Datapharm, a leading provider of medicines information in the UK, is excited to announce its continued expansion into Europe through a new strategic partnership with VIDAL. This collaboration will make Datapharm’s Scientific Response Document (SRD) Search technology accessible to healthcare professionals (HCPs) in France via VIDAL’s trusted medicines information platform. The partnership has already secured interest from 11 world-leading pharmaceutical companies.
Many HCPs struggle to find reliable answers online to their questions about medicines. To address this need, Datapharm collaborated with Medical Information Leaders in Europe (MILE) to develop innovative SRD search technology. The technology enables HCPs to retrieve accurate responses 24/7 and has already been successfully adopted in both the UK and Germany. Now, by integrating this innovative technology into VIDAL’s trusted platform, the collaboration will provide HCPs in France with the most comprehensive and up-to-date medicines information available.
VIDAL provides up-to-date information on medicines and treatments, hosting content from French Authorities as well as pharmaceutical companies. With more than 300 million page views annually, vidal.fr is the platform of choice for 327,000 French HCPs who use the service daily to find the right information on medical therapies.
Datapharm operates the electronic medicines compendium (emc), a trusted online resource for HCPs and patients which attracts over 85 million visitors annually. It hosts content from more than 320 global pharmaceutical companies, providing up-to-date information on medicines licensed for the UK. This new partnership will significantly extend Datapharm’s reach, making its medicines information technology available to HCPs across Europe.
Rich Cooper, CEO of Datapharm, commented: “We are excited to partner with VIDAL to improve the quality and accessibility of essential medicines information in France. With SRD search now available to healthcare professionals in the UK, Germany, and France, we are making significant strides in our mission to provide healthcare professionals globally with the information they need to deliver the highest quality care to their patients."
Vincent Bouvier, Chairman of VIDAL Group, added: “We are pleased to partner with Datapharm to continue enhancing our medical and drug information services to HCPs in France. SRD Search creates a new and simple option for doctors to access qualitative, reliable data 24/7, whenever they need to make a prescription decision. The partnership further strengthens our position as the n°1 trusted source of information for HCPs in France.”
About Datapharm
Datapharm is a leading medicines information provider in the UK. Its medicines information database, emc (electronic medicines compendium) is the UK’s most comprehensive, trusted and accessible source of information on medicines, listing more than 10,000 medicines and attracting a growing audience of over 85 million visitors per year.
As a data company, Datapharm provides innovative solutions to support the Life Sciences and wider Healthcare sectors in their work with medicines information, serving more than 320 Pharma companies in the UK.
Home - electronic medicines compendium (emc)
About VIDAL Group
VIDAL Group offers decision and information systems, clinical decision support, and prescription safety solutions, as well as practice management software, contributing to the continuous improvement of medical practice. VIDAL disseminates its data and services through all types of digital platforms used by healthcare professionals: medical software, web, mobile. Relying on a multilingual knowledge base, with over 400 employees in France, Germany and Spain, VIDAL Group is a major player in the field of medical decision & information systems providing its solutions in 30 countries. In Europe, they are used by more than 700,000 healthcare professionals and VIDAL contributes to many innovative projects aiming to mitigate risks related to the use of health products. Since 2016, VIDAL Group is part of the M3 group, a global player in digital health and leader in Asia and Japan. M3 is listed on the Tokyo Stock Exchange (2413.T)
About SRD Search
Scientific Response Documents (SRDs) are developed by Pharma to address frequently asked questions about medicines. They provide essential information that enables HCPs to evaluate the treatment’s appropriateness for specific circumstances, conditions, and patients. SRD search technology, developed with MILE (Medical Information Leaders in Europe), enables HCPs to search online and retrieve accurate responses they can trust to their specific questions about medicines.